New Integrase Inhibitor Matches Existing HIV Tx (CME/CE)
(MedPage Today) -- Once-daily bictegravir was highly potent and well tolerated in phase II study
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news
More News: Infectious Diseases | Study